185110-06-9

Basic information

• Product Name: 2-(3,4-DICHLORO-PHENYL)-PIPERAZINE
• Synonyms: 2-(3,4-DICHLORO-PHENYL)-PIPERAZINE;Piperazine, 2-(3,4-dichlorophenyl)-;2-(3,4-Dichlorophenyl)piperazine 2HCl
• CAS NO: 185110-06-9
• Molecular Formula: C₁₀H₁₂Cl₂N₂
• Molecular Weight: 231.12
• Product Categories: pharmacetical
• Mol File: 185110-06-9.mol

Chemical Properties

• Boiling Point: 348.1°Cat760mmHg
• Flash Point: 164.3°C
• Appearance: /
• Density: 1.238g/cm³
• Vapor Pressure: 5.14E-05mmHg at 25°C
• Refractive Index: 1.549
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(3,4-DICHLORO-PHENYL)-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3,4-DICHLORO-PHENYL)-PIPERAZINE(185110-06-9)
• EPA Substance Registry System: 2-(3,4-DICHLORO-PHENYL)-PIPERAZINE(185110-06-9)

Safety Data

• Hazardous Substances Data: 185110-06-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(3,4-DICHLORO-PHENYL)-PIPERAZINE is used as a precursor in the synthesis of various pharmaceutical drugs, primarily for the development of antipsychotic and antihistaminic medications. Its unique structure allows it to serve as a building block for creating new therapeutic agents.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2-(3,4-DICHLORO-PHENYL)-PIPERAZINE is utilized for its potential therapeutic effects in neurological and psychiatric disorders. Its ability to interact with specific receptors and pathways makes it a valuable compound for exploring novel treatment options.
Used in Organic Synthesis:
2-(3,4-DICHLORO-PHENYL)-PIPERAZINE is also employed as an intermediate in organic synthesis. Its functional groups and structural features facilitate its use in creating a variety of complex organic molecules for different applications.
Used in Chemical Catalysis:
Furthermore, this compound has been investigated for its potential use as a ligand in chemical catalysis. Its ability to form stable complexes with metal ions can enhance the efficiency and selectivity of catalytic processes in various chemical reactions.

InChI:InChI=1/C10H12Cl2N2/c11-8-2-1-7(5-9(8)12)10-6-13-3-4-14-10/h1-2,5,10,13-14H,3-4,6H2

Upstream product

• 4530-20-5 BOC-glycine 
• 185110-30-9 2-(R,S)-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)piperazine 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 
• 7757-82-6 sodium sulfate 
• 107-15-3 ethylenediamine 
• 38923-36-3 2-(3,4-dichlorophenyl)-2-oxoacetaldehyde 
• 2632-10-2 2-bromo-1-(3,4-dichlorophenyl)ethanone 
• 163339-71-7 α-bromo-3,4-dichlorophenylacetic acid methyl ester 
• 6725-44-6 methyl 2-(3,4-dichlorophenyl)acetate 
• 334477-10-0 3-(3,4-dichloro-phenyl)-piperazin-2-one 

Downstream Products

• 185110-16-1 3-(3,4-dichloro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 185110-12-7 (+/-)-1-[[3,5-bis(trifluoromethyl)phenyl]-methyl]-3-(3,4-dichlorophenyl)-piperazine 
• 185110-18-3 2-(1-benzyl-piperidin-4-ylamino)-1-[2-(3,4-dichloro-phenyl)-piperazin-1-yl]-ethanone 
• 185110-07-0 1-[4-(3,5-bis-trifluoromethyl-benzyl)-2-(3,4-dichloro-phenyl)-piperazin-1-yl]-2-bromo-ethanone 
• 185110-17-2 4-[(1-benzyl-piperidin-4-ylamino)-acetyl]-3-(3,4-dichloro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 185108-18-3 (+/-)-4-[3,5-dimethylbenzoyl]-2-(3,4-dichlorophenyl)-1-[[[1-(phenylmethyl)-4-piperidinyl]amino]acetyl]piperazine 
• 185108-18-3 2-(1-Benzyl-piperidin-4-ylamino)-1-[(S)-2-(3,4-dichloro-phenyl)-4-(3,5-dimethyl-benzoyl)-piperazin-1-yl]-ethanone 
• 185108-18-3 2-(1-Benzyl-piperidin-4-ylamino)-1-[(R)-2-(3,4-dichloro-phenyl)-4-(3,5-dimethyl-benzoyl)-piperazin-1-yl]-ethanone 

Relevant articles and documents

Discovery of novel 2-(3-phenylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3β inhibitors

We herein describe the results of further evolution of glycogen synthase kinase (GSK)-3β inhibitors from our promising compounds containing a 2-phenylmorpholine moiety. Transformation of the morpholine moiety into a piperazine moiety resulted in potent GSK-3β inhibitors. SAR studies focused on the phenyl moiety revealed that a 4-fluoro-2-methoxy group afforded potent inhibitory activity toward GSK-3β. Based on docking studies, new hydrogen bonding between the nitrogen atom of the piperazine moiety and the oxygen atom of the main chain of Gln185 has been indicated, which may contribute to increased activity compared with that of the corresponding phenylmorpholine analogues. Effect of the stereochemistry of the phenylpiperazine moiety is also discussed.

Synthesis and NK1/NK2 binding activities of a series of diacyl-substituted 2-arylpiperazines

The synthesis and binding affinity for hNK1 and hNK2 receptors of a series of diacyl substituted 2-aryl piperazines are described. SAR evaluation led to the racemic derivative 11g as an apparent dual inhibitor. Chiral chromatographic separation of 11g led to the observation that NK1 activity was shown by one enantiomer (13a) and NK2 activity was shown by the other enantiomer (13b). X-ray crystallographic analysis of the crystalline di-BOC derivative of the NK2 active piperazine (15) showed that the 2R configuration was associated with NK2 activity. Further derivatization indicated that dual NK1/NK2 activity could be built into the 2R series.

SPIRO-SUBSTITUTED AZACYCLIC-SUBSTITUTED PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS

The invention relates to compounds of the formula STR1 wherein Z, R c, y, m, u, Ar 2, n, X, R c', I and Ar 2 are as described herein. These compounds are neurokinin antagonists. These compounds are useful in the treatment of chronic airway diseases such as asthma.